This product is no longer in stock
This medication is prescribed in the following cases:
Ibrutinib should not be uses in patients diagnosed with severe hepatic impairment or hepatic disease, that correspond to the Child-Pugh scale, class C.
The most commonly reported adverse reactions (≥20%) in patients diagnosed with B-cell malignancies (such as MCL, CLL/SLL, WM and MZL) were rash, bruising, anemia, neutropenia, hemorrhage, pyrexia, musculoskeletal pain, nausea, fatigue, thrombocytopenia and diarrhea. The most common adverse reactions (≥20%) in patients with cGVHD were diarrhea, hemorrhage, anemia, thrombocytopenia, muscle spasms, pneumonia, stomatitis, nausea, fatigue and bruising.
Pharmacyclics LLC, Sunnyvale, USA
Also known as: Ibrutinib, Ibrunib, Ibrutix, Ibruxen, Butinib, Lucibru, Ibrutinix